oral glp-1 agonist approved GLP-1: A Needle-Free Solution for Weight Loss FDA Approves Oral Semaglutide as
Description
A study published last summer by JAMA Oncology looked at GLP-1 use and 14 obesity-related cancers and found that while the weight-loss drug lowered the risk of most cancers, there was a nonsignificant increased risk of kidney cancer particularly among people younger than 65
doi: 10.1016/j.dsx.2018.03.002 44 McCleanPLHlscherC
Cai HY, Yang D, Qiao J, Yang JT, Wang ZJ, Wu MN, et al
Regalado, A
The original drug candidate had pharmacokinetics that were suitable for daily dosing, and also dose limiting GLP-1R mediated GI adverse effects in healthy 41 participants and those with T2D 42
